Thread: Vitamin K-2
View Single Post
Old Tue Sep 4, 2012, 10:13 PM
tom30 tom30 is offline
Join Date: Sep 2010
Location: Brooklyn, New York
Posts: 108
This may be what Les is referencing, Les, please post your progress.

Vitamin K2 And Vitamin D3 Combination Therapy May Increase Red Blood Cell and Platelet Counts In Low-Risk MDS Patients
2 Comments By Nina Duong
Published: Jul 19, 2010 12:04 pm
Vitamin K2 And Vitamin D3 Combination Therapy May Increase Red Blood Cell and Platelet Counts In Low-Risk MDS Patients

For patients with low-risk myelodysplastic syndromes (MDS), a combination therapy of vitamins K2 and D3 may improve low red blood cell and low platelet counts, according to a Phase 2 clinical trial conducted by Japanese researchers and published in the journal Leukemia Research.

While treatment options exist for low-risk MDS patients, such as Revlimid (lenalidomide), Vidaza (azacitidine), and Dacogen (decitabine), patients are not always responsive to such therapies. Researchers, therefore, are always looking for treatment alternatives.

The Japanese researchers explored vitamins K2 and D3 as alternative treatment options for low-risk, elderly MDS patients.

Previous reports have shown that vitamin K2 treatment can improve blood cell counts. Vitamins related to D3 have also demonstrated therapeutic effects. Vitamin D3 may enhance the effects of vitamin K2.

The researchers divided the study into two phases: an initial treatment regimen of only vitamin K2, followed by a combination therapy of vitamins K2 and D3. For the first part of the study, 38 patients who had not had any form of MDS treatment for four weeks (except transfusions) received 15 mg of vitamin K2 three times a day over the course of 16 weeks. At the end of the treatment course, patients who did not respond started taking a capsule of vitamin D3 along with the vitamin K2 for another 16 weeks.

Researchers found that out of 38 patients, five (13 percent) responded to the vitamin K2 treatment. Of the 24 patients who had low red blood cell counts, four (17 percent) showed improved red blood cell counts after the vitamin K2 treatment. Of the 24 patients with low platelet count, five (21 percent) showed improved platelet counts. The researchers noted that in four patients, both the red blood cell and platelet counts improved at the same time.

Six patients initially required platelet transfusions. After treatment, one of these patients no longer required transfusions. However, none of the 10 patients requiring red blood cell transfusions became transfusion-independent after treatment.

Twenty patients who did not show any improvement in blood cell count continued taking vitamin D3 in addition to the vitamin K2. With this combination therapy, the response rate increased to 30 percent. Forty-five percent of patients experienced improved red blood cell counts, while 30 percent of patients showed improved platelet counts. One patient no longer required red blood cell and platelet transfusions.

Both the vitamin K2 treatment as well as the combination treatment of vitamins K2 and D3 did not have any effect on white blood cell count.

The researchers found that patients who responded to the combination treatment initially had lower red blood cell counts and higher white blood cell counts than patients who did not respond to treatment.

Additionally, the researchers also found that red blood cell counts improved in patients with or without high-risk chromosomal abnormalities, which suggests that chromosomal abnormalities may not affect the efficacy of the combination therapy.

Reports of side effects were very minimal. The side effects themselves, including nausea, stomach pain, and skin rash, were mild.

Based on the response rates and minimal side effects, the researchers concluded that combination therapy with vitamins K2 and VD3 has the potential to increase red blood cell and platelet counts for elderly patients with low-risk MDS.

They added that further studies will be needed to clarify the role of vitamin D3 and to determine how long the effects of the combination therapy last.
Tom- 62 yrs old, dx-eosinophilic fasciitis 2004, 1 yr prednisone resolves EF- now low counts, HGB has been ok... EF has been associated with MDS along with AA.
Reply With Quote